...
首页> 外文期刊>OncoTargets and therapy >Postchemotherapy sarcoma as a somatic-type malignancy derived from the gonadal yolk sac tumor in a patient with 46, XY pure gonadal dysgenesis
【24h】

Postchemotherapy sarcoma as a somatic-type malignancy derived from the gonadal yolk sac tumor in a patient with 46, XY pure gonadal dysgenesis

机译:化学治疗后肉瘤是源自性腺卵黄囊肿瘤的躯体型恶性肿瘤,患有46例XY纯性腺发育不全的患者

获取原文

摘要

46, XY pure gonadal dysgenesis (PGD) is characterized as a female phenotype with strip-like gonads, which has a high tendency to develop into gonadal tumors. Somatic-type malignancies of germ cell tumors (SMs of GCTs) refer to the presence of malignant non-germ cell histologies admixed with GCTs, which are usually chemoresistant and indicate poor prognosis. This case report aimed to analyze the special histological type of GCTs and the importance of salvage surgery in the treatment of refractory GCTs. We report a unique case of gonadal yolk sac tumor (YST) transformed into SMs in a patient with 46, XY PGD. This 18-year-old woman underwent laparoscopic pelvic tumor resection, considered her first surgery, 2?years ago, and pathology revealed YST with initial alpha-fetoprotein (AFP) level measuring 3,000?ng/mL. She underwent seven cycles of chemotherapy, and the AFP level decreased to within a normal range after the second cycle. However, a computed tomography scan after the seventh cycle revealed abdominal and pelvic metastases, and vaginal bleeding was continuously observed. Laparoscopic exploration and laparotomy with tumor subtotal resection were performed. A pathology report showed SMs (sarcoma) derived from YST. Whole exome sequencing demonstrated that the main somatic mutation was a non-synonymous mutation of KRAS (c.182AG), and this result did not show any indications for targeted drugs. She received three cycles of PEI (cisplatin, etoposide, and ifosfamide) chemotherapy but showed no response. She refused to undergo further treatment and has been alive with the disease for 7?months. This suggests that SMs may be one of the reasons for chemoresistance of refractory GCTs, and salvage surgery may be one of the most effective treatments for this patient. Targeted therapy may be a new choice for chemoresistant GCTs, but drug selection must be based on gene sequencing, and its efficacy still needs to be verified by further study.
机译:46. XY纯性腺发育不全(PGD)的特征是具有条状性腺的女性表型,极易发展为性腺肿瘤。生殖细胞肿瘤(GCT的SM)的体细胞型恶性肿瘤是指恶性的非生殖细胞组织学与GCT混合存在,通常具有化学抗性,预后不良。该病例报告旨在分析GCT的特殊组织学类型以及抢救性手术在难治性GCT中的重要性。我们报告一个独特的案例,在46​​岁的XY PGD患者中,性腺卵黄囊肿瘤(YST)转化为SM。这位18岁的妇女在2年前接受了腹腔镜盆腔肿瘤切除术,被认为是她的首次手术,并且病理显示YST的初始甲胎蛋白(AFP)水平> 3,000?ng / mL。她经历了七个化疗周期,第二个周期后AFP水平降至正常范围。然而,在第七个周期后的计算机断层扫描显示腹部和骨盆转移,并且连续观察到阴道出血。进行了腹腔镜探查和剖腹术并肿瘤全切除。病理报告显示源自YST的SM(肉瘤)。整个外显子组测序表明,主要的体细胞突变是KRAS的非同义突变(c.182A> G),并且该结果并未显示出靶向药物的任何适应症。她接受了三个周期的PEI(顺铂,依托泊苷和异环磷酰胺)化疗,但未见反应。她拒绝接受进一步的治疗,并且已经存活了7个月。这表明,SMs可能是难治性GCT耐药的原因之一,而挽救手术可能是该患者最有效的治疗方法之一。靶向疗法可能是化疗耐药GCT的新选择,但是药物选择必须基于基因测序,其疗效仍需进一步研究验证。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号